New hope for better blood sugar control in type 1 diabetes without weight gain
NCT ID NCT06762314
Summary
This study is testing whether adding either empagliflozin or semaglutide to standard insulin therapy can help overweight adults with type 1 diabetes better control their blood sugar levels. The goal is to see if these medications can lower long-term blood sugar (HbA1c) without causing dangerous low blood sugar or extra weight gain, which are common problems with high-dose insulin. Researchers will compare the two medications over three months in about 105 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tanta Unuversity
RECRUITINGTanta, 31527, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.